Medicines Formulary - search results for ""

Search results for ""

Drug name	NICE TAs	Comments	Subchapter
Asciminib	TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors		8.1
Ascorbic acid tablets			9.6
Asfotase alfa		NHSE commissioned	9.8
Asparaginase 10,000 units injection (5 vials)			8.1
Aspirin 300mg dispersible tablets		Topical analgesia - for gargling	4.7
Aspirin dispersible tablets			2.9
Aspirin suppositories			4.7
Atenolol tablets			2.4
Atezolizumab (Tecentriq®)	TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer		8.2
Atezolizumab (Tecentriq®)	TA492 - Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable TA520 - Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy TA525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy TA333 - Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment TA584 - Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer TA666 - Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma TA705 - Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer	Hospital use only	8.1

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.